ArticlePakistan journal of medical sciences2025
Efficacy of acupoint injection of recombinant human erythropoietin in the treatment of postoperative hemorrhagic anemia in elderly patients with femoral intertrochanteric fracture.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of acupoint injection of recombinant human erythropoietin (rHuEPO) in the treatment of postoperative hemorrhagic anemia in elderly patients with femoral intertrochanteric fracture (FIF). Methodology: This retrospective cohort analysis was conducted at Zhejiang Provincial Tongde Hospital. The research data were obtained from 60 elderly patients with hemorrhagic anemia after FIF surgery who were treated from April 2022 to December 2023. Patients who received acupoint injection of rHuEPO (acupoint group) were matched with the cohort of patients who underwent conventional subcutaneous injection of rHuEPO (subcutaneous group) in a 1:1 ratio, 30 patients in each group. The postoperative clinical efficacy, levels of blood routine indicators, coagulation function, transfusion status, and incidence of adverse reactions were compared between the two groups. Results: The clinical efficacy in the acupoint group was higher than that in the subcutaneous group (P<0.05). One day after surgery, there was no significant difference in blood routine indicators between the two groups (P>0.05). Seven and 14 days after surgery, the levels of red blood cell (RBC), hemoglobin (Hb), and hematocrit (HCT) in both groups increased, and were higher in the acupoint group than in the subcutaneous group (P<0.05). There were significant time-dependent changes in coagulation parameters - prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FIB) - in both groups at 1, 7, and 14 days after surgery (P<0.05), without significant differences between the two groups (P>0.05). The blood transfusion in the acupoint group was lower than that in the subcutaneous group (P<0.05). Conclusions: Compared with the conventional subcutaneous injection, acupoint injection of rHuEPO seems to be more effective in treating elderly patients with hemorrhagic anemia after FIF surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.